PE20171798A1 - Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada - Google Patents
Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforiladaInfo
- Publication number
- PE20171798A1 PE20171798A1 PE2017001625A PE2017001625A PE20171798A1 PE 20171798 A1 PE20171798 A1 PE 20171798A1 PE 2017001625 A PE2017001625 A PE 2017001625A PE 2017001625 A PE2017001625 A PE 2017001625A PE 20171798 A1 PE20171798 A1 PE 20171798A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfatase
- acetylgalactosamine
- galns
- enzyme
- highly active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a una formulacion que comprende una enzima N-acetilgalactosamina-6-sulfatasa (GALNS) humana recombinante purificada, buffer fosfato para reducir la desfosforilacion de la enzima y uno o mas agentes estabilizadores seleccionados de sales de aminoacidos, buffers de aminoacido, surfactantes y polioles, donde la formulacion tiene pH 5.0-5.8. Dicha GALNS es util en el diagnostico, profilaxis o tratamiento de enfermedades y condiciones, tales como las enfermedades por almacenamiento lisosomal que son ocasionadas por o estan asociadas con una deficiencia en la enzima GALNS, por ejemplo, la Mucopolisacaridosis IVa (MPS IVa o sindrome de Morquio A)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36671410P | 2010-07-22 | 2010-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171798A1 true PE20171798A1 (es) | 2017-12-28 |
Family
ID=44543776
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001625A PE20171798A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
| PE2013000110A PE20131140A1 (es) | 2010-07-22 | 2011-07-22 | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| PE2017001626A PE20171799A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000110A PE20131140A1 (es) | 2010-07-22 | 2011-07-22 | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| PE2017001626A PE20171799A1 (es) | 2010-07-22 | 2011-07-22 | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8765437B2 (es) |
| EP (1) | EP2595650B1 (es) |
| JP (2) | JP6030553B2 (es) |
| KR (2) | KR101598897B1 (es) |
| CN (1) | CN103037895B (es) |
| AR (2) | AR082319A1 (es) |
| AU (1) | AU2011280937B2 (es) |
| BR (1) | BR112013001558B1 (es) |
| CA (2) | CA3146151A1 (es) |
| CL (2) | CL2013000219A1 (es) |
| CY (1) | CY1118934T1 (es) |
| DK (1) | DK2595650T3 (es) |
| ES (1) | ES2616263T3 (es) |
| HR (1) | HRP20170245T1 (es) |
| HU (1) | HUE033163T2 (es) |
| IL (2) | IL224125B (es) |
| LT (1) | LT2595650T (es) |
| MX (1) | MX341838B (es) |
| PE (3) | PE20171798A1 (es) |
| PL (1) | PL2595650T3 (es) |
| PT (1) | PT2595650T (es) |
| RS (1) | RS55669B1 (es) |
| RU (1) | RU2607376C2 (es) |
| SG (1) | SG187580A1 (es) |
| SI (1) | SI2595650T1 (es) |
| SM (1) | SMT201700106B (es) |
| WO (1) | WO2012012718A2 (es) |
| ZA (1) | ZA201300286B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032074T2 (en) * | 2008-01-18 | 2017-08-28 | Biomarin Pharm Inc | Preparation and use of active, highly phosphorylated, human lisosomal sulfatase enzymes |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| WO2013119715A1 (en) * | 2012-02-07 | 2013-08-15 | Saint Louis University | Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US11529397B2 (en) | 2018-01-22 | 2022-12-20 | Saint Louis University | Method of treating mucopolysaccharidosis type IVA |
| AU2014243749A1 (en) | 2013-03-13 | 2015-08-06 | Shire Human Genetic Therapies, Inc. | Method of characterizing lysosomal enzymes |
| WO2014143622A1 (en) * | 2013-03-13 | 2014-09-18 | Seattle Genetics, Inc. | ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCs |
| WO2014201220A1 (en) * | 2013-06-12 | 2014-12-18 | The Board Of Trustees Of The University Of Illinois | Methods for detecting prostate cancer |
| EP3019521A1 (en) | 2013-07-12 | 2016-05-18 | EMD Millipore Corporation | A method of determining virus removal from a sample containing a target protein using activated carbon |
| US20170191041A1 (en) * | 2014-07-11 | 2017-07-06 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
| US10472615B2 (en) | 2016-01-21 | 2019-11-12 | Saint Louis University | Reduced immunogenic proteins for lysosomal storage disorders |
| WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| WO2019045149A1 (en) * | 2017-08-31 | 2019-03-07 | Green Cross Corporation | PROCESS FOR PURIFYING SULFATASE PROTEIN |
| RU2763990C2 (ru) * | 2020-02-19 | 2022-01-12 | Акционерное общество "ГЕНЕРИУМ" | Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки |
| WO2021216460A1 (en) * | 2020-04-19 | 2021-10-28 | Figene, Llc | Gene modified fibroblasts for therapeutic applications |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| TW202403043A (zh) * | 2022-03-18 | 2024-01-16 | 美商健臻公司 | 重組人類酸性鞘磷脂酶醫藥組合物及方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| JPS62122588A (ja) | 1985-11-22 | 1987-06-03 | Taiyo Fishery Co Ltd | 純コンドロイチナ−ゼの製造法 |
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US7083793B2 (en) | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| RU2195492C2 (ru) * | 2000-09-04 | 2002-12-27 | Институт физиологии Коми научного центра Уральского отделения РАН | Способ получения пектолитического ферментного препарата |
| EP1395669B1 (en) | 2001-01-26 | 2009-07-22 | Selexis S.A. | Matrix attachment regions and methods for use thereof |
| JP2006508643A (ja) * | 2002-07-01 | 2006-03-16 | アーキオン ライフ サイエンシーズ エルエルシー ディー／ビー／エー バイオ−テクニカル リソーセズ ディビジョン | グルコサミンおよびｎ−アセチルグルコサミン製造のためのプロセスおよび材料 |
| NZ603330A (en) | 2003-02-11 | 2015-02-27 | Shire Human Genetic Therapies | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies |
| JP2007277094A (ja) * | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
| BRPI0518661A2 (pt) * | 2004-12-22 | 2008-12-02 | Ambrx Inc | mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante |
| CA2649538C (en) * | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
| US20080231439A1 (en) | 2007-03-22 | 2008-09-25 | Inventec Corporation | Activity Detection Circuit for a Storage Device |
| CA2904458C (en) * | 2007-11-30 | 2017-07-25 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| HUE032074T2 (en) * | 2008-01-18 | 2017-08-28 | Biomarin Pharm Inc | Preparation and use of active, highly phosphorylated, human lisosomal sulfatase enzymes |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
-
2011
- 2011-07-21 AR ARP110102649A patent/AR082319A1/es not_active Application Discontinuation
- 2011-07-22 US US13/188,907 patent/US8765437B2/en active Active
- 2011-07-22 WO PCT/US2011/045011 patent/WO2012012718A2/en active Application Filing
- 2011-07-22 ES ES11751689.8T patent/ES2616263T3/es active Active
- 2011-07-22 AU AU2011280937A patent/AU2011280937B2/en active Active
- 2011-07-22 RS RS20170165A patent/RS55669B1/sr unknown
- 2011-07-22 PE PE2017001625A patent/PE20171798A1/es unknown
- 2011-07-22 PT PT117516898T patent/PT2595650T/pt unknown
- 2011-07-22 LT LTEP11751689.8T patent/LT2595650T/lt unknown
- 2011-07-22 KR KR1020137004487A patent/KR101598897B1/ko active IP Right Grant
- 2011-07-22 BR BR112013001558-6A patent/BR112013001558B1/pt active IP Right Grant
- 2011-07-22 EP EP11751689.8A patent/EP2595650B1/en active Active
- 2011-07-22 PE PE2013000110A patent/PE20131140A1/es not_active Application Discontinuation
- 2011-07-22 SI SI201131104A patent/SI2595650T1/sl unknown
- 2011-07-22 CA CA3146151A patent/CA3146151A1/en active Pending
- 2011-07-22 KR KR1020157007141A patent/KR101949906B1/ko active IP Right Grant
- 2011-07-22 CA CA2805673A patent/CA2805673C/en active Active
- 2011-07-22 SG SG2013004841A patent/SG187580A1/en unknown
- 2011-07-22 DK DK11751689.8T patent/DK2595650T3/en active
- 2011-07-22 PL PL11751689T patent/PL2595650T3/pl unknown
- 2011-07-22 RU RU2013107765A patent/RU2607376C2/ru active
- 2011-07-22 MX MX2013000908A patent/MX341838B/es active IP Right Grant
- 2011-07-22 JP JP2013520881A patent/JP6030553B2/ja active Active
- 2011-07-22 CN CN201180035900.4A patent/CN103037895B/zh active Active
- 2011-07-22 PE PE2017001626A patent/PE20171799A1/es unknown
- 2011-07-22 HU HUE11751689A patent/HUE033163T2/en unknown
-
2013
- 2013-01-07 IL IL224125A patent/IL224125B/en active IP Right Grant
- 2013-01-11 ZA ZA2013/00286A patent/ZA201300286B/en unknown
- 2013-01-22 CL CL2013000219A patent/CL2013000219A1/es unknown
-
2014
- 2014-05-19 US US14/281,538 patent/US8940513B2/en active Active
- 2014-12-17 US US14/573,907 patent/US9567572B2/en active Active
-
2016
- 2016-07-15 JP JP2016140213A patent/JP2016178950A/ja not_active Withdrawn
-
2017
- 2017-02-15 HR HRP20170245TT patent/HRP20170245T1/hr unknown
- 2017-02-15 CY CY20171100207T patent/CY1118934T1/el unknown
- 2017-02-16 SM SM201700106T patent/SMT201700106B/it unknown
- 2017-03-02 CL CL2017000498A patent/CL2017000498A1/es unknown
-
2018
- 2018-06-26 IL IL260282A patent/IL260282B/en active IP Right Grant
-
2020
- 2020-07-31 AR ARP200102165A patent/AR119552A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171798A1 (es) | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada | |
| CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
| BR112012033197A2 (pt) | métodos e composições para liberação de cns de n-sulfatase de heparano. | |
| NL300874I2 (nl) | Elosulfase alfa | |
| NZ743008A (en) | Compositions and methods for internalizing enzymes | |
| MX2016002934A (es) | Inclusion del exon 2 inducida por antisentido en la alfa-glucosidasa ácida. | |
| CO6660439A2 (es) | Eliminación de serina proteasa por tratamiento con dióxido de silicona finamente dividido | |
| BR112017018383A2 (pt) | inclusão de éxon2 induzida por anti-sentido em alfa-glucosidase ácida | |
| BR112013027963A2 (pt) | "variante de subtilisina com atividade proteolítica, ácido nucleico, vetor de expressão, célula hospedeira, composição e método de limpeza". | |
| MX2013006234A (es) | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. | |
| BR112013023774A2 (pt) | inibidores de glicosilceramida sintase | |
| PE20191815A1 (es) | Formulaciones acuosas estables de adalimumab | |
| PE20170938A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
| BR112014032560A2 (pt) | células para produzir iduronato-2-sulfatase recombinante | |
| MX349992B (es) | Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe. | |
| RS52913B (en) | SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES | |
| CO6190603A2 (es) | Acido 7-(2-metilpiridin-3-il carbomoil)-4a-benzil-2-(trifluorometil)-1,2,3,4,4a, 9, 10, 10a-octahidro fenantren-2-il-2-fosfonico como moduladores del receptor glucocorticoide | |
| BR112013017884A2 (pt) | varredura de microcolônia encapsulada com gel | |
| MX344795B (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a. | |
| EP4241854A3 (en) | Lysosomal storage disease enzyme | |
| BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
| BR112021016878A2 (pt) | Formulações de proteína estáveis | |
| PE20141265A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| PH12014501555A1 (en) | Methods and compositions for modulating expression or activity of a rkd polypeptide in a plant | |
| BR112015011693A2 (pt) | composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos |